ATTR Cardiac Amyloidosis - Urine Nephrology Now

RHC Comprehensive Guide Restrictive vs Constrictive ATTR Cardiac Amyloidosis

Quick Navigation

Executive Summary 1. Introduction 2. Epidemiology 3. Pathophysiology 4. Clinical Presentation 5. Diagnosis 6. Differential Diagnosis 7. Treatment 8. Prognosis 9. Nephrology Considerations 10. Summary References

Executive Summary

Key Points

ATTR-CM is an underdiagnosed infiltrative cardiomyopathy resulting from extracellular deposition of misfolded transthyretin protein, producing restrictive physiology with preserved ejection fraction (1,2)
Wild-type ATTR-CM (ATTRwt) may affect 10–15% of older adults with HFpEF, with strong male predominance and typical onset after age 65 (2,3)
Ejection fraction is unreliable in restrictive cardiomyopathy; critically low cardiac output can coexist with preserved EF (1,4)
Congestive hepatopathy from ATTR-CM can produce imaging findings indistinguishable from cirrhosis; ascitic fluid analysis provides insight into sinusoidal integrity (5,6)
Noninvasive diagnosis: grade 2–3 uptake on Tc-99m PYP scintigraphy in the absence of monoclonal protein, with sensitivity > 99% and specificity approaching 100% (7)
Disease-modifying therapies — tafamidis and acoramidis — significantly reduce mortality and cardiovascular hospitalization (8,9)

1. Introduction and Clinical Relevance

Cardiac amyloidosis has undergone a paradigm shift from a rare, untreatable diagnosis to an increasingly recognized and therapeutically addressable cause of heart failure. The convergence of noninvasive diagnostic imaging, epidemiologic data revealing higher prevalence, and disease-modifying pharmacotherapy has driven this transformation (1).

ATTR-CM is of particular relevance to clinicians in nephrology, hepatology, and primary care because its clinical manifestations frequently masquerade as more common conditions — refractory ascites attributed to cirrhosis, progressive renal dysfunction from cardiorenal syndrome, or HFpEF managed with standard therapy that proves ineffective (1,4).

This review was developed from an illustrative clinical case in which a 75-year-old male (Patient A) with diuretic-refractory ascites and CT findings reported as cirrhosis was ultimately found to have severely elevated biventricular filling pressures with cardiogenic shock-range cardiac output (CI 1.15 L/min/m²) despite a preserved ejection fraction of 55%. The patient died before therapy could be initiated.

2. Epidemiology

ATTRwt-CM was historically considered rare and was previously termed "senile cardiac amyloidosis." Contemporary data indicate substantially higher prevalence. Autopsy studies have identified transthyretin amyloid deposits in approximately 25% of individuals older than 80 years (2,3).

Systematic screening has identified ATTR-CM in: approximately 13% of patients hospitalized with HFpEF, 16% of patients undergoing TAVR for severe aortic stenosis, and 5–9% of patients with bilateral carpal tunnel syndrome (2,3).

ATTRwt-CM predominantly affects elderly males (> 90% male; median age at diagnosis > 75 years). Hereditary ATTR-CM (ATTRv) results from pathogenic TTR gene variants, of which > 120 have been identified. The Val122Ile variant is present in approximately 3–4% of African Americans (1,2).

Clinical Pearl: Any male patient over 65 with unexplained HFpEF, particularly with increased wall thickness, bilateral carpal tunnel syndrome, lumbar spinal stenosis, or biceps tendon rupture, should be evaluated for ATTR-CM. These extracardiac manifestations may precede cardiac diagnosis by years (1,4).

3. Pathophysiology

3.1 Transthyretin Biology and Amyloidogenesis

Transthyretin (TTR) is a 55-kDa homotetrameric protein synthesized predominantly in the liver. In ATTR amyloidosis, tetramer destabilization leads to dissociation into monomers, which misfold and aggregate into insoluble amyloid fibrils (2,8).

In ATTRwt, the sequence is normal but age-related factors promote instability. In ATTRv, pathogenic variants directly destabilize the tetramer (2,9).

3.2 Cardiac Infiltration and Restrictive Physiology

Amyloid fibrils deposit in the myocardial interstitium, expanding the extracellular space and progressively increasing wall thickness and stiffness. This produces severely impaired diastolic filling with reduced stroke volume despite preserved systolic contraction (1,2).

The critical consequence is EF–cardiac output dissociation: a ventricle filling 50 mL and ejecting 28 mL produces an EF of 55% while delivering a stroke volume less than half of normal (1,4).

3.3 Congestive Hepatopathy

Elevated right atrial pressure transmits retrograde through hepatic veins into sinusoids. Chronic sinusoidal hypertension produces centrilobular necrosis, fibrosis, and nodular regeneration — indistinguishable from cirrhosis on cross-sectional imaging. This "cardiac cirrhosis" is distinct from primary liver disease: inflammation plays no significant role, and the histologic pattern differs (5,6).

3.4 Sinusoidal Physiology and Ascites Formation

Ascitic Fluid Parameter	Cirrhotic Ascites	Cardiac Ascites
SAAG	≥ 1.1 g/dL	≥ 1.1 g/dL
Ascitic fluid total protein	< 2.5 g/dL	≥ 2.5 g/dL
Sinusoidal fenestrations	Closed (capillarized)	Open (intact)
Hepatic synthetic function	Impaired	Preserved

In cirrhosis: Sinusoidal capillarization restricts protein passage → low-protein ascites. In cardiac congestion: Intact fenestrations allow free protein passage → high-protein ascites.

Warning: The ascitic fluid protein cutoff of 2.5 g/dL has sensitivity and specificity in the 70–80% range. Early cirrhosis may produce higher-protein ascites, and longstanding cardiac congestion may cause true secondary cirrhosis with low-protein ascites. The protein value is a Bayesian probability modifier, not a definitive test (10).

4. Clinical Presentation

4.1 The Preserved EF Trap

The cardinal presentation is progressive heart failure with preserved ejection fraction in an older male patient. The 2020 AHA Scientific Statement explicitly identifies preserved EF as the primary barrier to diagnosis (1).

The quantitative evidence is compelling:

Median diagnostic delay of 13 months from HF to ATTRwt diagnosis (Ladefoged et al., 2020) (14)
44% of patients initially misdiagnosed; diagnostic delay increases death risk 3- to 5-fold (Quarta et al., 2022) (15)
Only 10% of physicians systematically screen HFpEF patients for cardiac amyloidosis (Shchendrygina et al., 2024) (16)

Warning: Preserved EF is the primary cognitive trap driving diagnostic failure in cardiac amyloidosis. In any elderly patient with HFpEF — particularly males over 65 with unexplained LV hypertrophy, disproportionate symptoms, or diuretic resistance — the EF must not be used to exclude significant cardiac disease. The preserved EF is not reassuring; it is the disease's camouflage (1,14,15,16).

Echocardiographic clues: increased biventricular wall thickness (IVS > 12 mm), biatrial enlargement, thickened interatrial septum and valves, small LV cavity, restrictive diastolic filling. Global longitudinal strain (GLS) with apical sparing is a more sensitive indicator than EF (1,4).

ECG: low voltage in limb leads (25–40%), pseudo-infarction pattern, conduction abnormalities. The discordance between echo wall thickness and ECG voltage is an important clue.

4.2 Extracardiac Manifestations

Bilateral carpal tunnel syndrome (often preceding cardiac diagnosis by 5–10 years), lumbar spinal stenosis, spontaneous biceps tendon rupture, peripheral and autonomic neuropathy, GI dysmotility (1,4).

4.3 Hepatic and Ascitic Manifestations

CT/ultrasound may show nodular liver morphology interpreted as cirrhosis. Preserved serum albumin (≥ 3.5 g/dL) with massive ascites argues strongly against cirrhosis as the primary etiology (10).

Clinical Pearl: In anticoagulated patients with ascites, never use the INR to assess hepatic synthetic function or calculate MELD scores. A supratherapeutic INR on warfarin creates the misleading appearance of hepatic failure when the liver is functionally intact. Albumin and factor V are the interpretable markers.

4.4 Diuretic-Refractory Ascites

In the illustrative case, bumetanide 4 mg PO BID (~furosemide 320 mg daily), dapagliflozin 10 mg, and spironolactone 50 mg failed to prevent rapid reaccumulation of 5.7 liters of ascites. This degree of diuretic resistance — failure targeting three nephron segments — is a hallmark of severely compromised cardiac output driving cardiorenal physiology (11).

Mechanisms are multiplicative: critically reduced CO limits renal blood flow; elevated RA pressure (23 mmHg) reduces the transrenal perfusion gradient; gut edema impairs oral diuretic bioavailability; neurohormonal activation overwhelms the diuretic effect.

4.5 The Absence of Lower Extremity Edema

Patients with cardiac amyloidosis may present with massive ascites but minimal peripheral edema. This reflects preferential targeting of the splanchnic circulation — the hepatic venous bed experiences enormous hydrostatic pressure across uniquely permeable sinusoidal endothelium. "Massive ascites with dry legs" should prompt cardiac investigation rather than excluding it (5,6).

5. Diagnosis

5.1 The Diagnostic Algorithm

Step 1: Clinical Suspicion. HFpEF with increased wall thickness in an older patient, especially with extracardiac features. Discordance between echo wall thickness and ECG voltage (1,2).

Step 2: Monoclonal Protein Screening. Serum free light chains, serum protein immunofixation, and urine protein immunofixation must all be performed to exclude AL amyloidosis and enable interpretation of the scintigraphy result (4,7).

Step 3: Tc-99m Bone Scintigraphy. Tc-99m PYP/DPD/HMDP with planar and SPECT imaging at 1 and 3 hours.

Perugini Grade	Visual Description	H/CL Ratio (1 hour)
0	No myocardial uptake	< 1.0
1	Mild uptake, less than rib	1.0–1.5
2	Moderate uptake, equal to rib	≥ 1.5
3	Strong uptake, greater than rib	>> 1.5

Noninvasive Diagnostic Criteria for ATTR-CM (Gillmore et al., 2016): Grade 2 or 3 myocardial uptake on Tc-99m PYP/DPD/HMDP scintigraphy PLUS absence of monoclonal protein = diagnostic of ATTR-CM without endomyocardial biopsy (7).

Step 4: Genetic Testing. TTR gene sequencing distinguishes ATTRwt from ATTRv. A positive TTR gene test does NOT obviate the need for PYP scintigraphy — the gene test answers "what type?" while scintigraphy answers "is it there?" (4,7).

Clinical Pearl: Think of TTR gene testing as answering "what type?" while PYP scintigraphy answers "is it there?" A positive gene test without scintigraphic confirmation could lead to misattribution. The PYP scan is the linchpin of the noninvasive diagnostic pathway and cannot be bypassed.

5.2 The Role of Right Heart Catheterization

Invasive hemodynamic assessment is critically important when the clinical presentation is disproportionate to echocardiographic findings. In the illustrative case, echo suggested mild disease (EF 55%), while catheterization revealed cardiogenic shock-range hemodynamics (CI 1.15). RHC also excludes constrictive pericarditis, which requires different management.

5.3 Cardiac Magnetic Resonance Imaging

CMR with late gadolinium enhancement (LGE) and parametric mapping (native T1, ECV) provides supportive diagnostic information. Characteristic: diffuse subendocardial or transmural LGE, elevated native T1, increased ECV. Cannot reliably distinguish ATTR from AL (1,2).

Clinical Pearl: Very high NT-proBNP levels (disproportionate to clinical HF severity) combined with chronically elevated troponin in a patient with echocardiographic hypertrophic phenotype is strongly suggestive of cardiac amyloidosis (4).

6. Differential Diagnosis

Condition	Distinguishing Features
AL (light chain) amyloidosis	Monoclonal protein detected; rapid progression; multiorgan involvement including nephrotic syndrome; requires urgent chemotherapy
Hypertensive cardiomyopathy	History of hypertension; concentric hypertrophy without disproportionate diastolic dysfunction
Hypertrophic cardiomyopathy	Asymmetric septal hypertrophy; dynamic outflow obstruction; younger presentation; sarcomere mutations
Fabry disease	X-linked; alpha-galactosidase A deficiency; angiokeratomas; corneal opacities; younger onset
Constrictive pericarditis	Pericardial thickening/calcification; dip-and-plateau; ventricular interdependence; surgically treatable
Cardiac sarcoidosis	Younger patients; conduction disease; patchy LGE; PET avidity; responsive to immunosuppression
Iron overload cardiomyopathy	Low T2* on CMR; history of transfusions or hemochromatosis

7. Treatment

7.1 Disease-Modifying Therapy: TTR Stabilizers

Tafamidis (Vyndaqel/Vyndamax): Binds to TTR tetramer, preventing dissociation. The ATTR-ACT trial (Maurer et al., NEJM 2018): 441 patients, 30 months. All-cause mortality 29.5% vs. 42.9% placebo (p = 0.0006). Reduced CV hospitalization (0.48 vs. 0.70/year). Tafamidis free acid 61 mg is the current formulation (8).

Acoramidis (Attruby): Next-generation stabilizer achieving > 90% TTR stabilization. ATTRibute-CM trial (Gillmore et al., NEJM 2024): 632 patients, win ratio 1.8 (p < 0.0001). Composite of death/first CV hospitalization reduced 35% (HR 0.65; NNT 7). FDA-approved November 2024 (9).

7.2 Gene Silencing Therapies

RNA interference and antisense oligonucleotide therapies reduce hepatic TTR production 80–90%. Vutrisiran (RNAi, subcutaneous q3 months) demonstrated 28% reduction in composite of death and recurrent CV events in HELIOS-B (12). CRISPR-Cas9 gene editing (NTLA-2001) has shown > 90% sustained TTR knockdown after a single IV dose; phase 2/3 trials ongoing (2).

7.3 Anti-Amyloid Antibodies: Toward Disease Reversal

NI006 (ALXN2220): Monoclonal antibody that binds misfolded TTR amyloid and triggers phagocytic clearance. Phase 1 trial (Garcia-Pavia et al., NEJM 2023): at doses ≥ 10 mg/kg, reduced cardiac tracer uptake on bone scintigraphy and ECV on CMR over 12 months — the first direct evidence that amyloid fibrils can be pharmacologically removed from the human heart (13). Phase 3 trial underway.

Biological plausibility was reinforced by a 2023 NEJM correspondence reporting three patients with spontaneous near-complete regression of cardiac amyloidosis via endogenous anti-TTR amyloid antibodies (12).

7.4 Can ATTR-CM Be Cured? A Realistic Assessment

Therapeutic Class	Mechanism	Status	"Cure" Potential
TTR stabilizers (tafamidis, acoramidis)	Prevent tetramer dissociation	FDA-approved	No — slows progression, does not remove deposits
Gene silencers (vutrisiran, patisiran)	Reduce hepatic TTR production 80–90%	Approved (neuropathy); HELIOS-B positive	Partial — stops production; native clearance may slowly reduce burden
CRISPR gene editing (NTLA-2001)	Permanent TTR gene knockdown (> 90%)	Phase 2/3	Partial — single dose, permanent production halt
Anti-amyloid antibodies (NI006)	Phagocytic removal of deposited fibrils	Phase 3	Highest — direct amyloid removal demonstrated on imaging
Combination (silencer + depleter)	Halt production + remove deposits	Theoretical	Greatest — addresses both supply and accumulated burden

7.5 Heart Failure Management

Diuretics remain the cornerstone of volume management but frequently prove inadequate in advanced ATTR-CM. Strategies: conversion to IV loop diuretics, addition of metolazone or chlorothiazide for sequential nephron blockade, and serial large-volume paracentesis.

Warning: Beta-blockers and non-dihydropyridine calcium channel blockers should be avoided or used with extreme caution in cardiac amyloidosis. The stiff, infiltrated ventricle is rate-dependent for cardiac output — stroke volume is fixed, so CO is directly proportional to heart rate. Rate-slowing agents may precipitate hemodynamic collapse (1,4). Digoxin binds preferentially to amyloid fibrils, potentially causing toxicity at standard levels.

8. Prognosis

Untreated ATTRwt-CM: median survival approximately 2.5–3.5 years from diagnosis. Staging systems incorporating NT-proBNP, troponin T, and eGFR provide prognostic stratification (2,3).

With disease-modifying therapy: tafamidis reduced 30-month mortality from 42.9% to 29.5%. Acoramidis achieved 80.7% 30-month survival, approaching the 85% estimated for age-matched general population (8,9). Earlier treatment initiation confers greater benefit.

9. Special Considerations for Nephrology

9.1 Cardiorenal Syndrome

ATTR-CM with reduced CO and elevated right-sided pressures produces cardiorenal syndrome through: reduced renal arterial perfusion (forward failure), elevated renal venous pressure (congestive nephropathy), neurohormonal activation, and impaired diuretic delivery. This directly explains the diuretic resistance (11).

9.2 Renal Amyloid Deposition

While cardiac involvement dominates, TTR amyloid deposits can occur in the kidney, particularly in ATTRv. Manifests as proteinuria or progressive renal insufficiency. Monitor renal function and urinary protein in all ATTR-CM patients (4).

9.3 Diuretic Optimization in Low-Output States

Key principles: recognize impaired oral bioavailability from gut edema; use IV diuretics when oral response is inadequate; sequential nephron blockade; monitor electrolytes; avoid excessive preload reduction in the rate-dependent amyloid ventricle.

9.4 Drug Dosing Considerations

Both tafamidis and acoramidis are hepatically metabolized — no renal dose adjustment needed. However, ATTRibute-CM excluded eGFR < 30, and limited data exist in advanced CKD or dialysis (9).

9.5 Transplant Considerations

Combined heart-liver transplantation has been performed for ATTRv. With gene silencing therapies available, isolated heart transplant combined with pharmacologic TTR suppression is an emerging alternative (2,4).

10. Summary and Key Teaching Points